MRF 25th Anniversary: Managing Immunotherapy-Related Treatment Side Effects
March 24, 2021For our 25th anniversary, we share a guest blog from Douglas B. Johnson, MD, MSCI, from Vanderbilt Medical Center and recipient of a research grant provided by the MRF/MRF Breakthrough Consortium: “Patient with metastatic melanoma” – these words carri …
Leading Skin Cancer Organizations Urge the FDA to Ban Tanning Beds for Minors
March 12, 2021WASHINGTON, DC – The Melanoma Research Foundation (MRF) recently signed- on to a letter from the National Council of Skin Cancer Prevention (NCSCP) urging the U.S. Food and Drug Administration (FDA) to finalize the proposed rules entitled General and P …
FDA Grants Alkermes Orphan Drug Designation for the Treatment of Mucosal Melanoma
March 11, 2021WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has recently granted orphan drug designation for the treatment of mucosal melanoma to Alkermes’ investigational engineered interleukin-2 (IL-2) variant immunotherapy, nemvaleukin alfa (“nemva …
#EyeGetDilated: Alton Pace in Memory of Daryl Pace
February 26, 2021Guest blog from Alton Pace in memory of his half-sister Daryl who passed away from ocular melanoma: “Take care of your eyeballs!” This is what my sister Daryl would often say to me years before her ocular melanoma (OM) diagnosis. Being a teenager at th …
A Focus on Rare Melanoma Subtypes
February 26, 2021Guest blog post from Mark Weinzierl, MRF board member and ocular melanoma survivor: My name is Mark Weinzierl and I am currently a board member of the Melanoma Research Foundation (MRF), the largest independent organization devoted to melanoma. My inte …
Recent Comments